Do analysts recommend GTBP or CYPH?

Cypherpunk Technologies has a consensus target price of $0.90, suggesting a potential upside of 39.73%. Given Cypherpunk Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Cypherpunk Technologies is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, GTBP or CYPH?

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GT Biopharma N/A N/A -$28.35M -$6.33 N/A Cypherpunk Technologies N/A N/A $4.82M -$0.02 N/A

Is GTBP or CYPH more profitable?

GT Biopharma's return on equity of 0.00% beat Cypherpunk Technologies' return on equity. Company Net Margins Return on Equity Return on Assets GT Biopharma N/A N/A -102.03% Cypherpunk Technologies N/A -48.33% -42.21%

Do analysts recommend MCRB or GTBP?

Seres Therapeutics presently has a consensus target price of $17.00, indicating a potential upside of 114.11%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MCRB or GTBP more profitable?

GT Biopharma's return on equity of 0.00% beat Seres Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Seres Therapeutics N/A -130.29% -35.35% GT Biopharma N/A N/A -102.03%

Does the media prefer MCRB or GTBP?

In the previous week, Seres Therapeutics had 3 more articles in the media than GT Biopharma. MarketBeat recorded 5 mentions for Seres Therapeutics and 2 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 1.90 beat Seres Therapeutics' score of 1.03 indicating that GT Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Positive

Do analysts recommend HYFT or GTBP?

MindWalk currently has a consensus target price of $5.00, suggesting a potential upside of 208.64%. Given MindWalk's stronger consensus rating and higher probable upside, research analysts plainly believe MindWalk is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MindWalk 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HYFT or GTBP more profitable?

GT Biopharma has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. GT Biopharma's return on equity of 0.00% beat MindWalk's return on equity. Company Net Margins Return on Equity Return on Assets MindWalk -66.79% -69.37% -39.74% GT Biopharma N/A N/A -102.03%

Does the media favor HYFT or GTBP?

In the previous week, MindWalk and MindWalk both had 2 articles in the media. GT Biopharma's average media sentiment score of 1.90 beat MindWalk's score of 0.89 indicating that GT Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MindWalk 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Positive

Do analysts rate MNOV or GTBP?

MediciNova presently has a consensus price target of $8.33, suggesting a potential upside of 486.85%. Given MediciNova's stronger consensus rating and higher possible upside, analysts plainly believe MediciNova is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediciNova 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MNOV or GTBP more profitable?

GT Biopharma has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. GT Biopharma's return on equity of 0.00% beat MediciNova's return on equity. Company Net Margins Return on Equity Return on Assets MediciNova -1,962.98% -27.28% -25.24% GT Biopharma N/A N/A -102.03%

Does the media refer more to MNOV or GTBP?

In the previous week, MediciNova had 2 more articles in the media than GT Biopharma. MarketBeat recorded 4 mentions for MediciNova and 2 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 1.90 beat MediciNova's score of 0.52 indicating that GT Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediciNova 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Positive

Do analysts recommend GTBP or CTOR?

Citius Oncology has a consensus target price of $6.00, suggesting a potential upside of 751.91%. Given Citius Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Citius Oncology is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Citius Oncology 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better earnings and valuation, GTBP or CTOR?

Citius Oncology is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GT Biopharma N/A N/A -$28.35M -$6.33 N/A Citius Oncology N/A N/A -$24.76M -$0.47 N/A

Is GTBP or CTOR more profitable?

GT Biopharma's return on equity of 0.00% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets GT Biopharma N/A N/A -102.03% Citius Oncology N/A -99.47% -42.16%

Does the media prefer GTBP or CTOR?

In the previous week, Citius Oncology had 1 more articles in the media than GT Biopharma. MarketBeat recorded 3 mentions for Citius Oncology and 2 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 1.90 beat Citius Oncology's score of 1.32 indicating that GT Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Positive Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

GT Biopharma (GTBP) Competitors

$0.49 +0.00 (+0.88%)

Closing price 07/1/2026 04:00 PM Eastern

Extended Trading

$0.49 -0.01 (-1.62%)

As of 07/1/2026 07:58 PM Eastern

Compare

GTBP vs. CYPH, MCRB, HYFT, MNOV, and CTOR

Should you buy GT Biopharma stock or one of its competitors? MarketBeat compares GT Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GT Biopharma include Cypherpunk Technologies (CYPH), Seres Therapeutics (MCRB), MindWalk (HYFT), MediciNova (MNOV), and Citius Oncology (CTOR). These companies are all part of the "pharmaceutical products" industry.

How does GT Biopharma compare to Cypherpunk Technologies?

GT Biopharma (NASDAQ:GTBP) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

Cypherpunk Technologies has a consensus target price of $0.90, suggesting a potential upside of 39.73%. Given Cypherpunk Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Cypherpunk Technologies is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

GT Biopharma has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market.

8.2% of GT Biopharma shares are held by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are held by institutional investors. 3.4% of GT Biopharma shares are held by insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, GT Biopharma had 1 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 2 mentions for GT Biopharma and 1 mentions for Cypherpunk Technologies. GT Biopharma's average media sentiment score of 1.90 beat Cypherpunk Technologies' score of 1.89 indicating that GT Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
GT Biopharma	Very Positive
Cypherpunk Technologies	Very Positive

Cypherpunk Technologies is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

GT Biopharma's return on equity of 0.00% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	N/A	-102.03%
Cypherpunk Technologies	N/A	-48.33%	-42.21%

Summary

Cypherpunk Technologies beats GT Biopharma on 8 of the 13 factors compared between the two stocks.

How does GT Biopharma compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Seres Therapeutics has higher revenue and earnings than GT Biopharma. Seres Therapeutics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	97.29	$5.70M	-$5.17	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A

Seres Therapeutics presently has a consensus target price of $17.00, indicating a potential upside of 114.11%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

GT Biopharma's return on equity of 0.00% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	-130.29%	-35.35%
GT Biopharma	N/A	N/A	-102.03%

In the previous week, Seres Therapeutics had 3 more articles in the media than GT Biopharma. MarketBeat recorded 5 mentions for Seres Therapeutics and 2 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 1.90 beat Seres Therapeutics' score of 1.03 indicating that GT Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Positive

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 8.2% of GT Biopharma shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by company insiders. Comparatively, 3.4% of GT Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Seres Therapeutics has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

Summary

Seres Therapeutics beats GT Biopharma on 10 of the 14 factors compared between the two stocks.

How does GT Biopharma compare to MindWalk?

MindWalk (NASDAQ:HYFT) and GT Biopharma (NASDAQ:GTBP) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

GT Biopharma has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. GT Biopharma's return on equity of 0.00% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-66.79%	-69.37%	-39.74%
GT Biopharma	N/A	N/A	-102.03%

6.7% of MindWalk shares are owned by institutional investors. Comparatively, 8.2% of GT Biopharma shares are owned by institutional investors. 6.8% of MindWalk shares are owned by company insiders. Comparatively, 3.4% of GT Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MindWalk has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

MindWalk currently has a consensus target price of $5.00, suggesting a potential upside of 208.64%. Given MindWalk's stronger consensus rating and higher probable upside, research analysts plainly believe MindWalk is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

MindWalk has higher revenue and earnings than GT Biopharma. MindWalk is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$17.59M	4.25	-$21.69M	-$0.20	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A

In the previous week, MindWalk and MindWalk both had 2 articles in the media. GT Biopharma's average media sentiment score of 1.90 beat MindWalk's score of 0.89 indicating that GT Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MindWalk	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Positive

Summary

MindWalk beats GT Biopharma on 9 of the 15 factors compared between the two stocks.

How does GT Biopharma compare to MediciNova?

MediciNova (NASDAQ:MNOV) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

MediciNova presently has a consensus price target of $8.33, suggesting a potential upside of 486.85%. Given MediciNova's stronger consensus rating and higher possible upside, analysts plainly believe MediciNova is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

MediciNova has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

MediciNova has higher revenue and earnings than GT Biopharma. MediciNova is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	170.47	-$12M	-$0.23	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A

GT Biopharma has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. GT Biopharma's return on equity of 0.00% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,962.98%	-27.28%	-25.24%
GT Biopharma	N/A	N/A	-102.03%

9.9% of MediciNova shares are held by institutional investors. Comparatively, 8.2% of GT Biopharma shares are held by institutional investors. 14.0% of MediciNova shares are held by company insiders. Comparatively, 3.4% of GT Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, MediciNova had 2 more articles in the media than GT Biopharma. MarketBeat recorded 4 mentions for MediciNova and 2 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 1.90 beat MediciNova's score of 0.52 indicating that GT Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediciNova	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Positive

Summary

MediciNova beats GT Biopharma on 11 of the 16 factors compared between the two stocks.

How does GT Biopharma compare to Citius Oncology?

GT Biopharma (NASDAQ:GTBP) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

8.2% of GT Biopharma shares are owned by institutional investors. Comparatively, 70.5% of Citius Oncology shares are owned by institutional investors. 3.4% of GT Biopharma shares are owned by company insiders. Comparatively, 9.8% of Citius Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Citius Oncology is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

Citius Oncology has a consensus target price of $6.00, suggesting a potential upside of 751.91%. Given Citius Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Citius Oncology is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

GT Biopharma has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.47, indicating that its stock price is 247% more volatile than the broader market.

In the previous week, Citius Oncology had 1 more articles in the media than GT Biopharma. MarketBeat recorded 3 mentions for Citius Oncology and 2 mentions for GT Biopharma. GT Biopharma's average media sentiment score of 1.90 beat Citius Oncology's score of 1.32 indicating that GT Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Positive
Citius Oncology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GT Biopharma's return on equity of 0.00% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	N/A	-102.03%
Citius Oncology	N/A	-99.47%	-42.16%

Summary

Citius Oncology beats GT Biopharma on 10 of the 13 factors compared between the two stocks.

Get GT Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GTBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GTBP vs. The Competition

Export

Metric	GT Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$17.66M	$3.67B	$6.79B	$12.59B
Dividend Yield	N/A	2.21%	2.66%	6.15%
P/E Ratio	-0.08	21.28	27.41	25.26
Price / Sales	N/A	324.37	533.25	101.17
Price / Cash	32.73	141.54	47.99	59.26
Price / Book	2.15	8.71	10.96	6.62
Net Income	-$28.35M	$23.87M	$3.57B	$336.83M
7 Day Performance	18.72%	4.34%	2.89%	3.19%
1 Month Performance	5.74%	6.62%	3.70%	0.86%
1 Year Performance	-84.06%	61.64%	34.39%	27.51%

GT Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GTBP GT Biopharma	0.6989 of 5 stars	$0.49 +0.9%	N/A	-85.5%	$17.66M	N/A	N/A	8	News Coverage Positive News
CYPH Cypherpunk Technologies	2.5641 of 5 stars	$0.65 -11.9%	N/A	+117.4%	$69.07M	N/A	N/A	40	Positive News Analyst Forecast Gap Up
MCRB Seres Therapeutics	3.7845 of 5 stars	$7.02 +6.4%	$22.00 +213.4%	-25.8%	$67.98M	$1.15M	N/A	330	Short Interest Decrease
HYFT MindWalk	3.1593 of 5 stars	$1.47 -1.9%	$5.00 +239.9%	N/A	$67.90M	$17.59M	N/A	80	News Coverage Gap Down
MNOV MediciNova	3.2599 of 5 stars	$1.35 +3.8%	$8.33 +517.3%	+11.8%	$66.45M	$410K	N/A	10	News Coverage Short Interest Decrease High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GTBP) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GT Biopharma (GTBP) Competitors

GTBP vs. CYPH, MCRB, HYFT, MNOV, and CTOR

How does GT Biopharma compare to Cypherpunk Technologies?

Summary

How does GT Biopharma compare to Seres Therapeutics?

Summary

How does GT Biopharma compare to MindWalk?

Summary

How does GT Biopharma compare to MediciNova?

Summary

How does GT Biopharma compare to Citius Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP vs. The Competition

GT Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GT Biopharma (GTBP) Competitors

GTBP vs. CYPH, MCRB, HYFT, MNOV, and CTOR

How does GT Biopharma compare to Cypherpunk Technologies?

Do analysts recommend GTBP or CYPH?

Which has more volatility and risk, GTBP or CYPH?

Do insiders and institutionals hold more shares of GTBP or CYPH?

Does the media favor GTBP or CYPH?

Which has better earnings & valuation, GTBP or CYPH?

Is GTBP or CYPH more profitable?

Summary

How does GT Biopharma compare to Seres Therapeutics?

Which has preferable valuation & earnings, MCRB or GTBP?

Do analysts recommend MCRB or GTBP?

Is MCRB or GTBP more profitable?

Does the media prefer MCRB or GTBP?

Do institutionals and insiders have more ownership in MCRB or GTBP?

Which has more volatility and risk, MCRB or GTBP?

Summary

How does GT Biopharma compare to MindWalk?

Is HYFT or GTBP more profitable?

Do insiders and institutionals hold more shares of HYFT or GTBP?

Which has more volatility & risk, HYFT or GTBP?

Do analysts recommend HYFT or GTBP?

Which has better valuation and earnings, HYFT or GTBP?

Does the media favor HYFT or GTBP?

Summary

How does GT Biopharma compare to MediciNova?

Do analysts rate MNOV or GTBP?

Which has more risk & volatility, MNOV or GTBP?

Which has stronger valuation & earnings, MNOV or GTBP?

Is MNOV or GTBP more profitable?

Do institutionals & insiders hold more shares of MNOV or GTBP?

Does the media refer more to MNOV or GTBP?

Summary

How does GT Biopharma compare to Citius Oncology?

Do institutionals and insiders hold more shares of GTBP or CTOR?

Which has better earnings and valuation, GTBP or CTOR?

Do analysts recommend GTBP or CTOR?

Which has more volatility & risk, GTBP or CTOR?

Does the media prefer GTBP or CTOR?

Is GTBP or CTOR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP vs. The Competition

GT Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools